Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2007 1
2008 1
2009 1
2010 2
2011 5
2012 7
2013 5
2014 2
2015 2
2016 8
2017 9
2018 9
2019 7
2020 10
2021 18
2022 6
2023 5
2024 7
2025 15
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Brunetti L, et al. Among authors: milano f. Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005. Cancer Cell. 2018. PMID: 30205049 Free PMC article.
Reply to Author.
Hill JA, Pergam SA, Boeckh M, Milano F. Hill JA, et al. Among authors: milano f. Biol Blood Marrow Transplant. 2018 Oct;24(10):2166. doi: 10.1016/j.bbmt.2018.06.030. Epub 2018 Jun 30. Biol Blood Marrow Transplant. 2018. PMID: 29969748 Free PMC article. No abstract available.
Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies.
Astigarraga CC, Mpms K, Iovino L, Milano F. Astigarraga CC, et al. Among authors: milano f. Blood Rev. 2025 Jul;72:101286. doi: 10.1016/j.blre.2025.101286. Epub 2025 Mar 21. Blood Rev. 2025. PMID: 40133165 Review.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a curative therapeutic option for patients with high-risk hematologic malignancies. ...Advances in in vivo graft manipulation techniques, such as post-transplant cyclophosphamide (PTCy) and ex viv …
Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a curative therapeutic option for patients with high-risk hemat …
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.
Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, Bhatt NS, Arrieta Bolaños E, Bolon YT, Gadalla SM, Grunwald MR, Krem MM, Lee SJ, Marsh SGE, Martino R, Mehta PA, Milano F, Prestidge T, Saultz JN, Shaw BE, Spellman SR, Choe H, Shaffer BC. Nath K, et al. Among authors: milano f. Blood Adv. 2025 Jul 22;9(14):3469-3478. doi: 10.1182/bloodadvances.2024014858. Blood Adv. 2025. PMID: 40048743 Free PMC article.
Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is unclear. We compared …
Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplant …
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. Cowan AJ, et al. Among authors: milano f. Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2. Lancet Oncol. 2023. PMID: 37414012 Free PMC article. Clinical Trial.
We included individuals aged 21 years or older with relapsed or refractory multiple myeloma, previous autologous stem-cell transplant or persistent disease after more than four cycles of induction therapy, and Eastern Cooperative Oncology Group performance status of 0-2, r …
We included individuals aged 21 years or older with relapsed or refractory multiple myeloma, previous autologous stem-cell transplant …
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
Mazziotta F, Martin LE, Egan DN, Bar M, Kinsella S, Paulson KG, Voillet V, Lahman MC, Hunter D, Schmitt TM, Duerkopp N, Yeung CCS, Tang TH, Gottardo R, Asano Y, Wilcox EC, Lee B, Zhang T, Lopedote P, Penter L, Wu CJ, Milano F, Greenberg PD, Chapuis AG. Mazziotta F, et al. Among authors: milano f. Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0. Nat Commun. 2025. PMID: 40473616 Free PMC article. Clinical Trial.
Relapsed and/or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. We previously reported that post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8(+) T cells engineered to express a Wilms T …
Relapsed and/or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. We …
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
Mazziotta F, Martin LE, Eagan DN, Bar M, Kinsella S, Paulson KG, Voillet V, Lahman MC, Hunter D, Schmitt TM, Duerkopp N, Yeung C, Tang TH, Gottardo R, Asano Y, Wilcox EC, Lee B, Zhang T, Lopedote P, Penter L, Wu CJ, Milano F, Greenberg PD, Chapuis AG. Mazziotta F, et al. Among authors: milano f. medRxiv [Preprint]. 2024 Dec 16:2024.12.13.24318504. doi: 10.1101/2024.12.13.24318504. medRxiv. 2024. PMID: 39763516 Free PMC article. Preprint.
Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was prevented by post-HCT immunotherapy with Epstein-Barr vir …
Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually f …
Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation.
Wenger DS, Triplette M, Crothers K, Cheng GS, Hill JA, Milano F, Shahrir S, Schoch G, Vande Vusse LK. Wenger DS, et al. Among authors: milano f. Biol Blood Marrow Transplant. 2020 Feb;26(2):413-420. doi: 10.1016/j.bbmt.2019.09.034. Epub 2019 Oct 9. Biol Blood Marrow Transplant. 2020. PMID: 31605819 Free PMC article.
Our current knowledge of idiopathic pneumonia syndrome (IPS) predates improved specificity in the diagnosis of IPS and advances in hematopoietic cell transplantation (HCT) and critical care practices. In this study, we describe and update the incidence, risk factors, and o …
Our current knowledge of idiopathic pneumonia syndrome (IPS) predates improved specificity in the diagnosis of IPS and advances in hematopoi …
Guidelines for Cord Blood Unit Selection.
Politikos I, Davis E, Nhaissi M, Wagner JE, Brunstein CG, Cohen S, Shpall EJ, Milano F, Scaradavou A, Barker JN; American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group. Politikos I, et al. Among authors: milano f. Biol Blood Marrow Transplant. 2020 Dec;26(12):2190-2196. doi: 10.1016/j.bbmt.2020.07.030. Epub 2020 Jul 28. Biol Blood Marrow Transplant. 2020. PMID: 32736011 Free article. Review.
Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful engraftment and survival after CB transplantation (CBT). However, unit selection can be complex because multiple characteristics must be considered including unit cell dose, donor-r …
Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful engraftment and survival after CB transplanta …
Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, Horwitz M, Milano F, Olson A, Spellman S, Wagner JE, Delaney C, Shpall E. Barker JN, et al. Among authors: milano f. Biol Blood Marrow Transplant. 2017 Jun;23(6):882-896. doi: 10.1016/j.bbmt.2017.03.006. Epub 2017 Mar 6. Biol Blood Marrow Transplant. 2017. PMID: 28279825 Free PMC article. Review.
Unrelated donor cord blood transplantation (CBT) results in disease-free survival comparable to that of unrelated adult donor transplantation in patients with hematologic malignancies. ...Targeted care strategies in CBT recipients can mitigate early transplantati …
Unrelated donor cord blood transplantation (CBT) results in disease-free survival comparable to that of unrelated adult donor tran …
103 results